Description:CO-1686, also known as Osimertinib, is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific mutations. It is characterized by its ability to target both activating mutations and the T790M resistance mutation in the EGFR gene, making it effective in patients who have developed resistance to earlier EGFR inhibitors. The compound exhibits high selectivity for mutant EGFR over wild-type EGFR, which helps to minimize off-target effects and enhance therapeutic efficacy. CO-1686 is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Its mechanism of action involves the inhibition of downstream signaling pathways that promote tumor growth and survival. Additionally, CO-1686 has been associated with a manageable safety profile, with common adverse effects including diarrhea, rash, and fatigue. Overall, CO-1686 represents a significant advancement in targeted cancer therapy, particularly for patients with specific EGFR mutations.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ami…](https://static.cymitquimica.com/products/IN/thumb/DA0039L5.jpg)
